The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
Total income for the period stood at Rs. 7101.28 crore
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Subscribe To Our Newsletter & Stay Updated
